<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017493</url>
  </required_header>
  <id_info>
    <org_study_id>02-032021-SULXAG/NO</org_study_id>
    <nct_id>NCT05017493</nct_id>
  </id_info>
  <brief_title>Treatment of Covid-19 With a Herbal Compound, Xagrotin</brief_title>
  <official_title>Treatment of Early-Stage Covid-19 With a Herbal Compound, Xagrotin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomad AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Directorate of health of Sulaimani, Iraq -KRG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biomad AS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective cohort trial. Adults with confirmed covid-19 disease not more than 10&#xD;
      days before enrollment date were recruited (n=361). Patients in same condition who had&#xD;
      treated with standard of care were randomly assigned to the control group (n=178). The&#xD;
      investigators analyzed the effect of a herbal compound, Xagrotin, and also investigated&#xD;
      impact of different characteristics for instance gender, age, duration of disease, smoking&#xD;
      habits and concomitant diseases on the outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective cohort trial that has been performed in an outpatient setting&#xD;
      (n=361). Adults with confirmed covid-19 disease not more than 10 days before enrollment date&#xD;
      were recruited. Patients in same condition who had treated with standard of care were&#xD;
      randomly assigned to the control group (n=178). The investigators analyzed the effect of a&#xD;
      herbal compound, Xagrotin, and also investigated impact of different characteristics for&#xD;
      instance gender, age, duration of disease, smoking habits and concomitant diseases on the&#xD;
      outcome. Adverse events were registered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Actual">February 8, 2021</completion_date>
  <primary_completion_date type="Actual">December 7, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalisation</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants who have been hospitalised for Covid-19</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">539</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Treatment arm received Xagrotin in combination to the standard of care for Covid19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the Control arm received the standard of care for Covid19.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Xagrotin</intervention_name>
    <description>A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or higher&#xD;
&#xD;
          -  Newly diagnosed (no longer than 10 days)&#xD;
&#xD;
          -  PCR or clinically confirmed Covid-19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe pulmonary disease&#xD;
&#xD;
          -  Severe cardiovascular disease&#xD;
&#xD;
          -  Severe hepatic disease&#xD;
&#xD;
          -  Severe renal disease&#xD;
&#xD;
          -  Diabetes mellitus type one&#xD;
&#xD;
          -  Metabolic acidosis&#xD;
&#xD;
          -  Oxygen saturation &lt;70%&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Concomitant treatment with anticoagulation drugs&#xD;
&#xD;
          -  Concomitant treatment with CYP3A4 medicines with narrow therapeutic window&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Directorate of health of Sulaimani, Iraq -KRG</name>
      <address>
        <city>Sulaymaniyah</city>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT05017493/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT05017493/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT05017493/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>September 21, 2021</submitted>
    <returned>September 24, 2021</returned>
    <submitted>October 2, 2021</submitted>
    <returned>October 5, 2021</returned>
    <submitted>October 6, 2021</submitted>
    <returned>October 6, 2021</returned>
    <submitted>October 19, 2021</submitted>
    <returned>October 19, 2021</returned>
    <submitted>November 1, 2021</submitted>
    <returned>November 8, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

